Cargando…

The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis

BACKGROUND: DIP is a new medical insurance payment system developed in China which was implemented in Guangzhou in January 2018, but few studies have focused on its intervention effect on the drug burden of elderly hypertensive patients. METHODS: Nine medical institutions in Guangzhou, China, were s...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Dongsheng, Lv, Duo, Wu, Jiaying, Li, Xin, Zhao, Qingwei, Lu, Xiaoyang, Li, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497050/
https://www.ncbi.nlm.nih.gov/pubmed/37705992
http://dx.doi.org/10.2147/RMHP.S418541
_version_ 1785105224557395968
author Hong, Dongsheng
Lv, Duo
Wu, Jiaying
Li, Xin
Zhao, Qingwei
Lu, Xiaoyang
Li, Lu
author_facet Hong, Dongsheng
Lv, Duo
Wu, Jiaying
Li, Xin
Zhao, Qingwei
Lu, Xiaoyang
Li, Lu
author_sort Hong, Dongsheng
collection PubMed
description BACKGROUND: DIP is a new medical insurance payment system developed in China which was implemented in Guangzhou in January 2018, but few studies have focused on its intervention effect on the drug burden of elderly hypertensive patients. METHODS: Nine medical institutions in Guangzhou, China, were selected, among which, daily full medical orders of elderly hypertensive inpatients from 2016 to 2020 were randomly collected. To assess the impact of DIP policy intervention on patient drug burden, we took the data after policy implementation in January 2018, as the intervention data, and applied a segmented regression model with interrupted time series to analyze the trend and changes in average daily drug costs per month and medication structure, stratified by age, sex, and inpatient department. RESULTS: A total of 34,276 elderly hypertensive patients’ daily full medical orders were obtained. The immediate level change of drug costs after intervention was −23.884 RMB/month (P = 0.652), and the trend change was statistically significant (−15.642 RMB/month, P = 0.002). The relative cumulative effect at the end of the study was −78.860% (95% CI: −86.087% to −69.076%), and the intervention effect was more significant in surgical and male patients. The analysis of drug structure changes showed that after the implementation of the DIP policy intervention, the proportion of anti-infective drugs, anti-tumor drugs, and biological products all showed a significant downward trend (P < 0.05), while nutritional drugs showed a significant upward trend (P = 0.011), but no immediate horizontal change in slope was observed. CONCLUSION: The typical practice in China showed that DIP policy intervention can improve the drug burden of elderly hypertensive hospitalized patients and has a stable long-term effect, and the intervention effect is not consistent across different clinical department and populations with different characteristics, and it would also cause changes in the medication structure.
format Online
Article
Text
id pubmed-10497050
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104970502023-09-13 The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis Hong, Dongsheng Lv, Duo Wu, Jiaying Li, Xin Zhao, Qingwei Lu, Xiaoyang Li, Lu Risk Manag Healthc Policy Original Research BACKGROUND: DIP is a new medical insurance payment system developed in China which was implemented in Guangzhou in January 2018, but few studies have focused on its intervention effect on the drug burden of elderly hypertensive patients. METHODS: Nine medical institutions in Guangzhou, China, were selected, among which, daily full medical orders of elderly hypertensive inpatients from 2016 to 2020 were randomly collected. To assess the impact of DIP policy intervention on patient drug burden, we took the data after policy implementation in January 2018, as the intervention data, and applied a segmented regression model with interrupted time series to analyze the trend and changes in average daily drug costs per month and medication structure, stratified by age, sex, and inpatient department. RESULTS: A total of 34,276 elderly hypertensive patients’ daily full medical orders were obtained. The immediate level change of drug costs after intervention was −23.884 RMB/month (P = 0.652), and the trend change was statistically significant (−15.642 RMB/month, P = 0.002). The relative cumulative effect at the end of the study was −78.860% (95% CI: −86.087% to −69.076%), and the intervention effect was more significant in surgical and male patients. The analysis of drug structure changes showed that after the implementation of the DIP policy intervention, the proportion of anti-infective drugs, anti-tumor drugs, and biological products all showed a significant downward trend (P < 0.05), while nutritional drugs showed a significant upward trend (P = 0.011), but no immediate horizontal change in slope was observed. CONCLUSION: The typical practice in China showed that DIP policy intervention can improve the drug burden of elderly hypertensive hospitalized patients and has a stable long-term effect, and the intervention effect is not consistent across different clinical department and populations with different characteristics, and it would also cause changes in the medication structure. Dove 2023-09-08 /pmc/articles/PMC10497050/ /pubmed/37705992 http://dx.doi.org/10.2147/RMHP.S418541 Text en © 2023 Hong et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Hong, Dongsheng
Lv, Duo
Wu, Jiaying
Li, Xin
Zhao, Qingwei
Lu, Xiaoyang
Li, Lu
The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis
title The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis
title_full The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis
title_fullStr The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis
title_full_unstemmed The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis
title_short The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis
title_sort influence of diagnosis intervention packet policy intervention on medication structure and drug cost of elderly hypertensive inpatients in china: a multicenter interrupted time-series analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497050/
https://www.ncbi.nlm.nih.gov/pubmed/37705992
http://dx.doi.org/10.2147/RMHP.S418541
work_keys_str_mv AT hongdongsheng theinfluenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis
AT lvduo theinfluenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis
AT wujiaying theinfluenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis
AT lixin theinfluenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis
AT zhaoqingwei theinfluenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis
AT luxiaoyang theinfluenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis
AT lilu theinfluenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis
AT hongdongsheng influenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis
AT lvduo influenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis
AT wujiaying influenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis
AT lixin influenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis
AT zhaoqingwei influenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis
AT luxiaoyang influenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis
AT lilu influenceofdiagnosisinterventionpacketpolicyinterventiononmedicationstructureanddrugcostofelderlyhypertensiveinpatientsinchinaamulticenterinterruptedtimeseriesanalysis